Valproate (Paternal exposure)

ASD (Autism spectrum disorder): Diagnosis/Risk

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18660
R80571
Meng_Norway (Controls exposed to LTG/LEV), 2026 Autism spectrum disorder (ASD) - At least 2 diagnoses on different dates ICD-9 and ICD-10: F84.xx (except F84.2x, F84.3x) - Follow up: between 6 and 12 years Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: Yes Paternal ASMs: monotherapy 1.66 [0.55;4.98]
excluded (control group)
7/319   10/730 17 319
ref
S18942
R80572
Meng_Norway (Controls unexposed, sick), 2026 Autism spectrum disorder (ASD) - At least 2 diagnoses on different dates ICD-9 and ICD-10: F84.xx (except F84.2x, F84.3x) - Follow up: between 6 and 12 years Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) population based cohort retrospective unexposed, sick Adjustment: Yes Paternal ASMs: monotherapy 1.48 [0.82;2.68] 7/304   1,199/121,306 1,206 304
ref
S18944
R80573
Meng_Taiwan (Controls unexposed, sick), 2026 Autism spectrum disorder (ASD) - At least 2 diagnoses on different dates ICD-9 and ICD-10: F84.xx (except F84.2x, F84.3x) - Follow up: between 6 and 12 years Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) population based cohort retrospective unexposed, sick Adjustment: Yes Paternal ASMs: monotherapy 1.14 [0.67;1.93] 15/543   10,373/500,498 10,388 543
ref
S18948
R80590
Razaz_Sweden, 2026 Autism spectrum disorder (ASD) - One diagnosis ICD-10 code for ASD: F84, excluding F84.2–F84.4 - Median age at the end of follow-up: 6.6 years Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) population based cohort retrospective exposed to other treatment, sick Adjustment: Yes Paternal ASMs: monotherapy 1.24 [0.84;1.83] 59/1,500   81/2,906 140 1,500
ref
S18654
R79304
Botton, 2025 Autism spectrum disorders - ICD10: F84 (excl F84.2-F84.3) - Median follow up (years): 11.9 (IQR [10.3 - 13.3]) for valproate; 11.2 (IQR [9.9 - 12.8]) for control Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) retrospective cohort (claims database) exposed to other treatment, sick Adjustment: Yes Paternal ASMs: monotherapy 1.04 [0.64;1.71] 53/3,484   28/2,041 81 3,484
ref
S18646
R79305
Christensen (Controls exposed to LTG/LEV), 2024 Autism spectrum disorder - ICD-10 code F84 (excluding F84.2-F84.4) - Median age [IQR] age at the end of follow-up: 10.6 [5.4-15.0] years for valproate; 5.5 [2.7-9.3] years for controls Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: Yes Paternal ASMs: monotherapy 0.69 [0.37;1.28]
excluded (control group)
24/961   31/1,401 55 961
ref
S18644
R79306
Christensen (Controls unexposed, general pop), 2024 Autism spectrum disorders - ICD10: F84 (excl F84.2-F84.4) - Median follow-up about 10 years (IQR 5-15) Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: No Paternal ASMs: monotherapy 0.82 [0.54;1.24]
excluded (control group)
-/1,017   24,479/1,234,017 - 1,017
ref
S18647
R79307
Christensen (Controls unexposed, sibling), 2024 Autism spectrum disorders - ICD10: F84 (excl F84.2-F84.4) - Median follow-up about 10 years (IQR 5-15) Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) population based cohort retrospective sibling excluded Adjustment: Yes Paternal ASMs: mono/polytherapy or not specified 0.54 [0.14;2.12]
excluded (control group)
7/303   17/381 24 303
ref
S18645
R79308
Christensen (Controls unexposed, sick), 2024 Autism spectrum disorders - ICD10: F84 (excl F84.2-F84.4) - Median follow-up about 10 years (IQR 5-15) Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) population based cohort retrospective unexposed, sick Adjustment: Yes Paternal ASMs: mono/polytherapy or not specified 0.85 [0.57;1.26] 27/1,052   298/11,308 325 1,052
ref
Total 5 studies 1.10 [0.89;1.35] 12,140 6,883
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Meng_Norway (Controls unexposed, sick), 2026Meng_Norway, 2026 1 1.48[0.82; 2.68]1,20630412%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: low Meng_Taiwan (Controls unexposed, sick), 2026Meng_Taiwan, 2026 2 1.14[0.67; 1.93]10,38854315%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: low Razaz_Sweden, 2026Razaz_Sweden, 2026 1.24[0.84; 1.83]1401,50028%ROB confusion: seriousROB selection: unclearROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Botton, 2025Botton, 2025 1.04[0.64; 1.71]813,48418%ROB confusion: moderateROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Christensen (Controls unexposed, sick), 2024Christensen, 2024 3 0.85[0.57; 1.26]3251,05227%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Total (5 studies) I2 = 0% 1.10[0.89; 1.35]12,1406,8830.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.10[0.89; 1.35]12,1406,8830%NAMeng_Norway (Controls unexposed, sick), 2026 Meng_Taiwan (Controls unexposed, sick), 2026 Razaz_Sweden, 2026 Botton, 2025 Christensen (Controls unexposed, sick), 2024 5 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.06[0.77; 1.46]11,9191,89919%NAMeng_Norway (Controls unexposed, sick), 2026 Meng_Taiwan (Controls unexposed, sick), 2026 Christensen (Controls unexposed, sick), 2024 3 exposed to other treatment, sickexposed to other treatment, sick 1.16[0.85; 1.57]2214,9840%NARazaz_Sweden, 2026 Botton, 2025 2 Tags Adjustment   - Yes  - Yes 1.10[0.89; 1.35]12,1406,8830%NAMeng_Norway (Controls unexposed, sick), 2026 Meng_Taiwan (Controls unexposed, sick), 2026 Razaz_Sweden, 2026 Botton, 2025 Christensen (Controls unexposed, sick), 2024 5 Paternal ASMs   - mono/polytherapy or not specified  - mono/polytherapy or not specified 0.85[0.57; 1.26]3251,052 -NAChristensen (Controls unexposed, sick), 2024 1   - monotherapy  - monotherapy 1.20[0.94; 1.53]11,8155,8310%NAMeng_Norway (Controls unexposed, sick), 2026 Meng_Taiwan (Controls unexposed, sick), 2026 Razaz_Sweden, 2026 Botton, 2025 4 All studiesAll studies 1.10[0.89; 1.35]12,1406,8830%NAMeng_Norway (Controls unexposed, sick), 2026 Meng_Taiwan (Controls unexposed, sick), 2026 Razaz_Sweden, 2026 Botton, 2025 Christensen (Controls unexposed, sick), 2024 50.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-0.70.80.3630.000Meng_Norway (Controls unexposed, sick), 2026Meng_Taiwan (Controls unexposed, sick), 2026Razaz_Sweden, 2026Botton, 2025Christensen (Controls unexposed, sick), 2024

Asymetry test p-value = 0.3847 (by Egger's regression)

slope=-0.4776 (0.5671); intercept=2.4477 (2.4108); t=1.0153; p=0.3847

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 18646, 18644, 18647, 18660

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.82[0.54; 1.24]24,4701,017 -NAChristensen (Controls unexposed, general pop), 2024 1 unexposed, sick controlsunexposed, sick controls 1.06[0.77; 1.46]11,9191,89919%NAMeng_Norway (Controls unexposed, sick), 2026 Meng_Taiwan (Controls unexposed, sick), 2026 Christensen (Controls unexposed, sick), 2024 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.07[0.82; 1.41]2936,2643%NAMeng_Norway (Controls exposed to LTG/LEV), 2026 Razaz_Sweden, 2026 Botton, 2025 Christensen (Controls exposed to LTG/LEV), 2024 4 siblingssiblings 0.54[0.14; 2.10]24303 -NAChristensen (Controls unexposed, sibling), 2024 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Ochmann (Autism spectrum disorders)Ochmann (Autism spectrum disorders) 1.09[0.82; 1.44]-Wwhatever (meta-analysis)Pat. genotoxic/epigeneticPaternal exposure: genotoxic/epigenetic window (0–xxx months preconception)studies TTT2 metaPregmetaPreg 1.10[0.89; 1.35]0%6,883----Meng_Norway (Controls unexposed, sick), 2026 Meng_Taiwan (Controls unexposed, sick), 2026 Razaz_Sweden, 2026 Botton, 2025 Christensen (Controls unexposed, sick), 2024 50.510.01.0